Digital Health
Gero Raises $6M for Physics-Powered GenAI Biotech
What You Should Know: Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round. This funding round…
What You Should Know:
- Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.
- This funding round positions Gero to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence. The round was led by Melnichek Investments, a Cyprus-based VC firm that seeks to improve the quality of human lives by funding and supporting promising, potentially high-impact, machine-learning startups, with the participation of VitaDAO and Leonid Lozner.
Exploring New Horizons with Cutting-Edge Generative AI Tools
By applying cutting-edge generative AI tools to analyze real-world longitudinal human health data, Gero is dedicated to finding novel cures for age-related diseases. Its goal is to unravel the mysteries behind human aging and halt the aging process.
“The large health model that we have trained is instrumental in the discovery of therapies targeting aging and age-related diseases, both in-house and via collaborations with pharmaceutical companies,” said Peter Fedichev, Gero co-founder and CEO. “Thanks to this recent funding from Melnichek Investments, coupled with their expertise in modern AI through backing many successful companies, we are now well positioned to accelerate our progress.”
Earlier this year, Gero announced a research partnership with Pfizer and is in talks with other pharmaceutical companies interested in addressing age-related diseases as a growing market. Gero’s advanced health model distinguishes the effects of aging from those of diseases, potentially transforming genetics-driven drug discovery for common conditions. Melnichek Investments recognized the potential in Gero’s mission to gain insights into the causes of age-related diseases and create new treatments using AI technology. Age-related diseases are complex and require an understanding of vast data sets beyond human capacity. Gero’s work emphasizes the importance of this realization and the solutions it offers. Gero is a leader in the emerging field of medical research, suggesting that aging can be treated and controlled with modern technology, rather than being an unavoidable part of human existence.
Keep it Short
By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
Seattle startup Olamedi building platform to automate health clinic communications
A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…
